logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12637414 B1

PDFFull Text
Date of Patent:
May. 26, 2026

Filed:

Jun. 03, 2022

Arylamides and methods of use thereof

Applicant:

Genzyme Corporation, Cambridge, MA (US);

Inventors:

Junkai Liao, Bridgewater, NJ (US);

Mark Munson, Bridgewater, NJ (US);

Zhongli Gao, Bridgewater, NJ (US);

Gregory Hurlbut, Bridgewater, NJ (US);

Hans Peter Nestler, Bridgewater, NJ (US);

Ingrid Mechin, Bridgewater, NJ (US);

Joseph Kim, Bridgewater, NJ (US);

Martin Smrcina, Bridgewater, NJ (US);

Nina MA, Bridgewater, NJ (US);

Ronghua Li, Bridgewater, NJ (US);

Ryan Hartung, Bridgewater, NJ (US);

William Bock, Bridgewater, NJ (US);

Bertrand Vivet, Bridgewater, NJ (US);

Assignee:

Genzyme Corporation, Cambridge, MA (US);

Attorney:

Goodwin Procter LLP

Primary Examiner:

Jeffrey S Lundgren

Assistant Examiner:

W. Justin Youngblood

Int. Cl.
CPC ...
C07C 235/66 (2006.01); A61K 31/197 (2006.01); A61K 31/343 (2006.01); A61K 31/381 (2006.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/517 (2006.01); A61K 45/06 (2006.01); C07C 309/68 (2006.01); C07C 309/75 (2006.01); C07C 323/19 (2006.01); C07D 215/48 (2006.01); C07D 239/70 (2006.01); C07D 239/88 (2006.01); C07D 277/64 (2006.01); C07D 307/79 (2006.01); C07D 333/70 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07C 235/66 (2013.01); A61K 31/197 (2013.01); A61K 31/343 (2013.01); A61K 31/381 (2013.01); A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/517 (2013.01); A61K 45/06 (2013.01); C07C 309/68 (2013.01); C07C 309/75 (2013.01); C07C 323/19 (2013.01); C07D 215/48 (2013.01); C07D 239/70 (2013.01); C07D 239/88 (2013.01); C07D 277/64 (2013.01); C07D 307/79 (2013.01); C07D 333/70 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07C 2601/14 (2017.05); C07C 2603/74 (2017.05);
Abstract

The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Find Patent Forward Citations

Loading…